Using machine learning to predict radiation pneumonitis in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy

被引:74
|
作者
Valdes, Gilmer [1 ]
Solberg, Timothy D. [1 ]
Heskel, Marina [1 ]
Ungar, Lyle [2 ]
Simone, Charles B., II [1 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Comp & Informat Sci, 200 S 33Rd St, Philadelphia, PA 19104 USA
来源
PHYSICS IN MEDICINE AND BIOLOGY | 2016年 / 61卷 / 16期
关键词
radiation pneumonitis; stereotactic body radiation therapy (SBRT); non-small cell lung cancer; machine learning; Decision Trees; RUSBoost; Random Forests; DOSE-VOLUME HISTOGRAM; INDUCED PULMONARY TOXICITY; RADIOTHERAPY OUTCOMES; RISK;
D O I
10.1088/0031-9155/61/16/6105
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
To develop a patient-specific 'big data' clinical decision tool to predict pneumonitis in stage I non-small cell lung cancer (NSCLC) patients after stereotactic body radiation therapy (SBRT). 61 features were recorded for 201 consecutive patients with stage I NSCLC treated with SBRT, in whom 8 (4.0%) developed radiation pneumonitis. Pneumonitis thresholds were found for each feature individually using decision stumps. The performance of three different algorithms (Decision Trees, Random Forests, RUSBoost) was evaluated. Learning curves were developed and the training error analyzed and compared to the testing error in order to evaluate the factors needed to obtain a cross-validated error smaller than 0.1. These included the addition of new features, increasing the complexity of the algorithm and enlarging the sample size and number of events. In the univariate analysis, the most important feature selected was the diffusion capacity of the lung for carbon monoxide (DLCO adj%). On multivariate analysis, the three most important features selected were the dose to 15 cc of the heart, dose to 4 cc of the trachea or bronchus, and race. Higher accuracy could be achieved if the RUSBoost algorithm was used with regularization. To predict radiation pneumonitis within an error smaller than 10%, we estimate that a sample size of 800 patients is required. Clinically relevant thresholds that put patients at risk of developing radiation pneumonitis were determined in a cohort of 201 stage I NSCLC patients treated with SBRT. The consistency of these thresholds can provide radiation oncologists with an estimate of their reliability and may inform treatment planning and patient counseling. The accuracy of the classification is limited by the number of patients in the study and not by the features gathered or the complexity of the algorithm.
引用
收藏
页码:6105 / 6120
页数:16
相关论文
共 50 条
  • [21] Association Between Radiation Therapy Dose and Survival in Patients With Stage I Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
    Koshy, M.
    Malik, R.
    Sher, D. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S158 - S158
  • [22] Stereotactic body radiation therapy for stage I non-small cell lung cancer: a small academic hospital experience
    Factor, Oren B.
    Vu, Charles C.
    Schneider, Jeffrey G.
    Witten, Matthew R.
    Schubach, Scott L.
    Gittleman, Alicia E.
    Catell, Donna T.
    Haas, Jonathan A.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [23] Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer
    Crabtree, Traves D.
    Denlinger, Chadrick E.
    Meyers, Bryan F.
    El Naqa, Issam
    Zoole, Jennifer
    Krupnick, A. Sasha
    Kreisel, Daniel
    Patterson, G. Alexander
    Bradley, Jeffrey D.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2010, 140 (02): : 377 - 386
  • [24] Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer
    Lee, Percy
    Loo Jr, Billy W.
    Biswas, Tithi
    Ding, George X.
    El Naqa, Issam M.
    Jackson, Andrew
    Kong, Feng-Ming
    LaCouture, Tamara
    Miften, Moyed
    Solberg, Timothy
    Tome, Wolfgang A.
    Tai, An
    Yorke, Ellen
    Li, X. Allen
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (01): : 160 - 171
  • [25] Comorbidity is a Prognostic Factor in Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy
    Chipidza, F. E.
    Franco, I.
    Chen, Y. H.
    Baldini, E. H.
    Chen, A. B.
    Kozono, D. E.
    Mak, R. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E677 - E677
  • [26] Stereotactic Body Radiation Therapy and Surgery for Early Stage Non-Small Cell Lung Cancer
    Piperis, Maria
    Tsoukalas, Nikolaos
    JOURNAL OF INVESTIGATIVE SURGERY, 2018, 31 (05) : 448 - 449
  • [27] Advances in stereotactic body radiation therapy for early stage non-small cell lung cancer
    Brown, Andrea M.
    Mak, Raymond H.
    Kann, Benjamin H.
    CURRENT CHALLENGES IN THORACIC SURGERY, 2022, 4
  • [28] Survival is Increasing for Patients with Stage I Non-Small Cell Lung Cancer Treated With Primary Radiation Therapy: We are Making Progress in the Era of Stereotactic Body Radiation Therapy
    Shin, J.
    Russo, G. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 241 - 241
  • [29] Stereotactic Body Radiation Therapy for Patients with Early-Stage Non-small Cell Lung Cancer Inoperable
    Pham, L. V.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S518 - S518
  • [30] Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT)
    Pathak, Rima S.
    Pantarotto, Jason R.
    Cook, Graham
    Holmes, Oliver
    Cross, Peter
    MacRae, Robert M.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2019, 16 : 28 - 33